Juventas Therapeutics Inc., of Cleveland, presented top-line interim data from a phase II study evaluating the safety and efficacy of JVS-100 in patients with symptomatic ischemic cardiomyopathy at the European Society of Cardiology Heart Failure Congress in Athens, Greece.